ClinicalTrials.gg
Not yet recruitingNCT06755801MOTORSUpdated Jan 1, 2025

Nebivolol ANOCA Treatment Randomized Trial

A Phase 3 interventional study of Nevibolol and Placebo in ANOCA - Angina With Non-obstructive Coronary Arteries and Coronary Microvascular Dysfunction (CMD), sponsored by Spanish Society of Cardiology. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-01-01.

Sponsored by Spanish Society of Cardiology · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Sex
All
01

Study summary

To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.

Read the detailed description

Objective To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.

Hypothesis Treatment with titrated nebivolol will result superior to placebo in symptoms control in patients presenting with coronary microvascular disease (CMD).

Study design Prospective, multicenter, controlled, double-blinded, randomized clinical trial.

Inclusion criteria • Patients over 18 years old with symptoms or evidence of myocardial ischemia and coronary arteries without lesions or with epicardial lesions (\<50% by visual estimation or FFR >0.80 / RFR >0.90), and

  • CFR ≤ 2.0 and/or IMR≥25 Exclusion criteria Life expectancy \<1 year, inability to provide informed consent, severe valve disease, left ventricular ejection fraction \<30%, clinical contraindication for betablockers treatment.

Treatment arms Randomization will be performed after invasive diagnostic of CMD:

Study group: Nebivolol • Patients will start with a dose of 5 mg every 24 hours. Biweekly dose adjustments will be performed during the first two months, increasing the dose (if tolerated with respect to heart rate, blood pressure, and symptoms) up to a maximum of 20 mg/24 hours.

Control group: Placebo

  • Patients will be treated with one tablet every 24 hours. Primary endpoint: The effectiveness of nebivolol treatment in improving angina symptoms was measured using the SAQ questionnaire after 6 months of treatment.

Secondary endpoints • Quality of life at 6 months.

  • Functional capacity at 6 months.
  • Major cardiac events at 1 year.
02

Conditions studied

  • ANOCA - Angina With Non-obstructive Coronary Arteries
  • Coronary Microvascular Dysfunction (CMD)

Keywords

  • Coronary Microvascular Disease
  • Betablockers
  • Angina
03

In context

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

This study's planned enrollment of 150 is above the median of 79 across 63 interventional studies indexed under Microvascular Angina.

Browse Microvascular Angina studies →

Lead sponsor

Spanish Society of Cardiology is the lead sponsor of 23 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.

    • Presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months.
    • Absence of functionally significant epicardial coronary artery disease (FFR > 0.80).
    • Microvascular functional study showing CFR\< 2,0 and/or IMR ≥ 25.

Exclusion criteria

Exclusion Criteria:

  • Allergy or to the use of beta-blockers.
  • Indication for beta-blocker treatment due to another pathology.
  • Ventricular dysfunction ( \< 45%).
  • Percutaneous coronary revascularization in the last 6 months.
  • History of surgical revascularization.
  • First-degree atrioventricular block or bifascicular block.
  • Presence of hemodynamically significant valvulopathy.
  • Presence of cardiomyopathy or congenital cardiac anomaly.
  • Severe renal insufficiency ( \< 30 ml/min).
  • Liver failure (history of cirrhosis or transaminase elevation > 3 times the ).
  • Pregnant or lactating women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Active treatment group

    Nevibolol tratment

    Drug: Nevibolol

  • Placebo comparator
    Control group

    Placebo group

    Drug: Placebo

Interventions

  • DrugNevibolol

    Beta-blockers are the first-line treatment for patients with stable angina secondary to classic epicardial atherosclerotic disease, where their clinical benefits are well-established (4). However, their efficacy has not yet been demonstrated in ANOCA patients with MVD, where beta-blockers are frequently used due to their physiological plausibility. Beta-blockers act by competitively inhibiting catecholamine receptors. The therapeutic benefits of beta-blockade in patients with stable angina are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand depends on heart rate, contractility, and left ventricular wall tension, all of which are reduced with beta-adrenergic blockade. The reduction in wall tension is partly mediated by the antihypertensive action of these drugs. The decrease in heart rate occurs both at rest and during sympathetic activation such as exercise or stress. The negative inotropic effect of these drugs also contributes to reducing myocardial oxyg

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. SAQ questionnaire

    The pre-specified primary outcome criterion is the improvement in angina severity assessed by the Seattle Angina Questionnaire (SAQ SS - Summary Score) at 6 months from the start of treatment compared to baseline. It will be evaluated by the mean difference in change within the same patient in SAQ between the two groups at 6 months of treatment. The SAQ is a validated self-administered scale that allows assessment of angina severity, frequency, quality of life, and functional limitation. It is the most commonly used and validated patient-reported outcome measure for angina. The SAQ provides a scale for evaluating the severity of angina that has been shown to be valid, reproducible, and sensitive to changes.

    Time frame: 6 months

Secondary outcomes

  1. Quality of Life Status using the EuroQOL questionnaire (EQ5D-5L)

    Patient's quality of life in both treatment groups will be assessed using the EuroQOL questionnaire (EQ5D-5L). The EQ5D-5L is the most widely used instrument for assessing health-related quality of life.

    Time frame: 6 months

  2. the Brief Illness Perception Questionnaire (B-IPQ)

    Changes in disease perception will also be recorded using the Brief Illness Perception Questionnaire (B-IPQ)

    Time frame: 6 months

  3. anxiety and depression using PHQ-4

    Quality of Life Status

    Time frame: 6 months

  4. The treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM-9)

    Quality of Life Status

    Time frame: 6 months

  5. Functional Capacity

    Functional capacity in both groups will be objectively assessed by performing a baseline and 6-month exercise treadmill test (ergometry) according to the Bruce protocol. The evaluated parameter will be the total duration of maximum exercise (seconds).

    Time frame: 6 months

  6. Major Cardiac Events

    The presence of major cardiac events will be adjudicated by an Independent Events Committee. Major cardiac events are defined as death from any cause, acute myocardial infarction, and hospitalization due to unstable angina, stroke, or heart failure requiring hospitalization.

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Mar 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Jan 1, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Mar 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06755801
Lead sponsor
Spanish Society of Cardiology
Responsible party
Fernando Alfonso (Head of Cardiology Department. H. U. de la Princesa., Spanish Society of Cardiology) — Principal investigator
First posted
Jan 1, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Mar 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jan 1, 2025

Study contacts

FERNANDO RIVERO, MD,PHD
Contact
hemodinamicaprincesa@gmail.com
+34 915202470.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion